Ignite Creation Date:
2024-05-06 @ 4:09 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04897477
Status:
UNKNOWN
Last Update Posted:
2021-05-21
First Post:
2021-05-18
Brief Title:
Azacytidine Bendamustine Piamprizumab in RefractoryRelapsed B-cell Non-Hodgkins Lymphoma
Sponsor:
Chinese PLA General Hospital
Organization:
Chinese PLA General Hospital
Study Overview
Official Title:
An Open Label Single Arm Phase III in the Combination of Azacytidine Bendamustine and Piamprizumab in RefractoryRelapsed B-cell Non-Hodgkins
Status:
UNKNOWN
Status Verified Date:
2021-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open label single arm phase III for patients with rr Non-Hodgkins Lymphoma
The purpose is to evaluate the safety and efficacy of the combination with Azacytidine Bendamustine and Piamprizumab
The purpose is to evaluate the safety and efficacy of the combination with Azacytidine Bendamustine and Piamprizumab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None